moneyheap
OGN · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is Organon & Co. (OGN) stock moving?
OGN closed at 13.89 on Nov 10, the highest close in the 30-day window, but it has traded in a narrow 13.72-13.89 band with low daily volatility. That pattern, together with the pending Sun Pharma acquisition cited in the news, suggests the price is anchored to deal expectations rather than to fundamentals. The Q3 report showed revenue down 2% year over year, offset by higher net income and cash flow. Recent news flow is incremental: real-world HADLIMA switchback data (1.3%), VTAMA data presentations, and a $0.02 quarterly dividend payable Dec 10. Volume was 2.36M on Nov 10 against 3.95M on Nov 6, so the latest move did not come with unusual activity. The deal terms and closing timing are not in the provided data, which limits confidence in any directional call.
News behind the analysis
- Reported Saturday, Organon Presents Real-World Data At ACR Showing 1.3% Switchback Rate After Over 16,000 US Veterans Switched From HUMIRA To HADLIMAOrganon presented real-world data at the ACR meeting showing a 1.3% switchback rate among over 16,000 US veterans who moved from HUMIRA to HADLIMA.
- Organon Presents Real-World Evidence on HADLIMA Biosimilar Switch in VA Healthcare SystemNew real-world evidence presented at the ACR Annual Meeting shows significant cost savings and a low switchback rate when VA patients moved from HUMIRA to HADLIMA.
- Organon to Present New Data on VTAMA® (tapinarof) Cream at 2026 ACAAI Annual Scientific MeetingOrganon will present new clinical data on VTAMA cream 1% at the 2026 ACAAI Annual Scientific Meeting.
- Organon To Present New Analysis Of Phase 3 Data Evaluating VTAMA Cream In Patients With Atopic Dermatitis, At 2026 ACAAI Annual Scientific MeetingOrganon will present a new analysis of Phase 3 VTAMA cream data in atopic dermatitis patients at the 2026 ACAAI meeting.
- Organon Reports Third Quarter 2026 Financial ResultsQ3 2026 revenue fell 2% year over year while net income increased and cash flow was higher, with mixed product trends and a pending Sun Pharma deal.
- Organon Declares Quarterly DividendOrganon declared a $0.02 per share quarterly dividend, payable December 10, 2026, to holders of record as of November 9, 2026.
- Sun Pharmaceutical Reports Impact of Organon & Co. Acquisition Costs on Quarterly EarningsSun Pharma's quarterly net profit fell on exceptional charges tied to its proposed acquisition of Organon.
About Organon & Co.
Organon is a New Jersey-based drug company that Merck spun off in 2021. It sells women's health products such as the Nexplanon contraceptive implant, biosimilars, and a large portfolio of older branded medicines. In 2026 it agreed to be bought by Sun Pharma for $14.00 per share in cash, and the deal is still pending.
How it makes money
It sells prescription medicines around the world, with yearly revenue of roughly $6 billion. The largest share comes from established brands that have lost or are losing patent protection, such as cholesterol, respiratory and allergy drugs. The rest comes from women's health, led by Nexplanon and fertility products, and from biosimilars like Ontruzant, Renflexis and Hadlima. Revenue has been shrinking slightly, and the company carries a lot of debt.
What usually moves OGN
- Progress and approvals for the pending Sun Pharma cash buyout
- Nexplanon sales and US women's health demand
- Price erosion and generic competition on established brands
- Biosimilar uptake
- Debt levels and foreign-exchange effects